From Nasdaq:

Shares of Novo Nordisk have risen by over 200% in the last 3 years due to the success of its diabetes drug Ozempic. Potential biotech contenders to follow a similar trajectory include Madrigal Pharmaceuticals and Viking Therapeutics. Madrigal is developing a drug to treat NASH, a liver disease that affects around 1.5 million individuals in the U.S. Viking Therapeutics is also in the running thanks to its NASH and obesity programs. While both companies face challenges, their prospects are worth considering, but investing in pre-revenue biotech stocks like these involves significant risks.



Read more: 2 Rising Biotechs That Could Become the Next Novo Nordisk